ECSP992913A - ACID HYDROXAMIDES (4- ARYL SULFONYLAMINE) - TETRAHYDROPIRAN -4- CARBOXYLIC - Google Patents
ACID HYDROXAMIDES (4- ARYL SULFONYLAMINE) - TETRAHYDROPIRAN -4- CARBOXYLICInfo
- Publication number
- ECSP992913A ECSP992913A ECSP992913A ECSP992913A EC SP992913 A ECSP992913 A EC SP992913A EC SP992913 A ECSP992913 A EC SP992913A EC SP992913 A ECSP992913 A EC SP992913A
- Authority
- EC
- Ecuador
- Prior art keywords
- disease
- aortic aneurysm
- cerebral
- injury
- cancer
- Prior art date
Links
Abstract
Un compuesto de fórmula (gráfico), en la que Q es como se ha definido antes, que es útil en el tratamiento de un trastorno seleccionado del grupo formado por artritis (incluyendo osteo artritis y artritis reumatoide), enfermedad inflamatoria del intestino, enfermedad de Crohn, enfisema, enfermedad pulmonar obstructiva crónica, enfermedad de Alzheimer, toxidad en el transplante de un órgano caquexia, reacciones alérgicas, hipersensibilidad por contacto alérgica, cáncer, ulceración de tijidos, reestenosis, enfermedad periodontal, epidermólisis ampollosa, osteoporosis, falta de firmeza de implantes de articualciones artificiales, aterosclerosis (incluyendo ruptura de la placa aterosclerótica), aneurisma aórtico (incluyendo aneurisma aórtico abdomonal y aneurisma aórtico cerebral), insuficiencia cardiaca congestiva, infarto de miocardio, accidente cerebro vascular, isquemia cerebral, traumatismo craneal, lesión de la médula espinal, trastornos neurodegenerativos (agudos y crónicos), trastornos autoinmunes, enfermedad de Huntington, enfermedad de Parkinson, migraña, depresión, neuropatia periférica, dolor, angiopatia amiloide cerebral, potenciación nootrópica o cognitiva, esclerosis lateral amiotrófica, esclerosis múltiple, angiogénesis ocular, lesión corneal, degeneración macular, curación anómala de heridas, quemaduras, diabetes, invasión tumoral, crecimiento de tumor, metástasis tumoral, quemaduras corneales, escleritis, SIDA, septicemia y choque séptico. Además, los compuestos de la presente invención se pueden usar en terapia de combinación con fármacosantiinflamatorios no esteroideos (AINE) y analgésicos convencionales, y en combinación con fármacos citotóxicos como adriamicina, daunomicina, cis-platino, etopósido, taxol, taxótero y otros alcaloides como vincristina, en el tratamiento del cáncer.A compound of formula (graph), in which Q is as defined above, which is useful in the treatment of a disorder selected from the group consisting of arthritis (including osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, disease of Crohn's disease, emphysema, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity cachexia, allergic reactions, allergic contact hypersensitivity, cancer, ulceration of tissues, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, lack of firmness of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and cerebral aortic aneurysm), congestive heart failure, myocardial infarction, cerebrovascular accident, cerebral ischemia, head injury, spinal cord injury spinal, neurodegenerative disorders (acute and c autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognitive enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal healing of wounds, burns, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal burns, scleritis, AIDS, septicemia and septic shock. Furthermore, the compounds of the present invention can be used in combination therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and conventional pain relievers, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxater and other alkaloids such as Vincristine, in the treatment of cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP992913 ECSP992913A (en) | 1999-04-09 | 1999-04-09 | ACID HYDROXAMIDES (4- ARYL SULFONYLAMINE) - TETRAHYDROPIRAN -4- CARBOXYLIC |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP992913 ECSP992913A (en) | 1999-04-09 | 1999-04-09 | ACID HYDROXAMIDES (4- ARYL SULFONYLAMINE) - TETRAHYDROPIRAN -4- CARBOXYLIC |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP992913A true ECSP992913A (en) | 1999-06-11 |
Family
ID=42043902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP992913 ECSP992913A (en) | 1999-04-09 | 1999-04-09 | ACID HYDROXAMIDES (4- ARYL SULFONYLAMINE) - TETRAHYDROPIRAN -4- CARBOXYLIC |
Country Status (1)
Country | Link |
---|---|
EC (1) | ECSP992913A (en) |
-
1999
- 1999-04-09 EC ECSP992913 patent/ECSP992913A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5050369A1 (en) | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPI- RAN-4-CARBOXILICO | |
EP1539692A1 (en) | Furanone derivatives and methods of making same | |
DK1270024T3 (en) | Compositions and medical devices comprising bioabsorbable polymers grow of the alkyd type | |
EA199900641A1 (en) | Derivatives of arylsulfonylhydroxamic acid | |
AR009292A1 (en) | DERIVATIVES OF ACID ARILSULFONILAMINO HIDROXAMICO, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT | |
ES2552764T3 (en) | Methods for the treatment of various diseases and conditions, and compounds useful for them | |
EA200702216A1 (en) | COMPOSITIONS IN THE FORM OF NANOPARTICLES WITH CONTROLLED LIBERATION CONTAINING CYCLOSPORIN | |
CA2919532C (en) | Polymeric biomaterials derived from monomers comprising hydroxyacids and phenol compounds and their medical uses | |
UA99731C2 (en) | Crystalline polymorphic forms of n-(2-arylamino) aryl sulfonamides as inhibitors of mek, a composition (variants) and use | |
EA200901373A1 (en) | AMINOGETEROCYCLIC COMPOUNDS | |
TW200904418A (en) | Novel compounds as cannabinoid receptor ligands | |
CA2250295A1 (en) | Water soluble paclitaxel prodrugs | |
ECSP066561A (en) | ORGANIC COMPOUNDS | |
WO2006121560A8 (en) | Methods and compositions for treatment of cns disorders | |
TNSN04052A1 (en) | AZABICYCLIC SUBSTITUTED CONDENSED HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | |
ATE253918T1 (en) | USE OF HYMENIALDISINE AND ITS DERIVATIVES FOR THE PRODUCTION OF THERAPEUTIC AGENTS | |
WO2007061677A3 (en) | Spirolactam aryl cgrp receptor antagonists | |
CN113383019B (en) | Nitric oxide releasing antimicrobial polymers and scaffolds made therefrom and methods relating thereto | |
WO2000055159A3 (en) | Substituted aza-oxindole derivatives | |
ECSP992913A (en) | ACID HYDROXAMIDES (4- ARYL SULFONYLAMINE) - TETRAHYDROPIRAN -4- CARBOXYLIC | |
EP3555084B1 (en) | Thiazine derivatives as beta-secretase inhibitors and methods of use | |
WO2004072042A3 (en) | Quinoline derivative and their use for modulation of lxr activity | |
BRPI0509559A (en) | pyrazolamine compounds for the treatment of neurodegenerative disorders | |
HUE030650T2 (en) | 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof | |
KR20110039562A (en) | Isosorbide nitrates having vasodilating activity |